Synonyms: BMS-790052 | BMS790052 | Daklinza®
daclatasvir is an approved drug (EMA (2014), FDA (2015))
Compound class:
Synthetic organic
Comment: Daclatasvir is an orally available anti-hepatitis C virus (HCV) drug, It is a direct-acting inhibitor of the non-structural protein 5A (NS5A) replication complex of HCV [1]. Blocking NS5A function inhibits viral RNA replication and virion assembly.
|
|
References |
1. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle 2nd DR et al.. (2010)
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature, 465 (7294): 96-100. [PMID:20410884] |